Intercept Pharmaceuticals Inc.

106.11-4.14-3.76%Vol 1 292 4251Y Perf -6.88%
Jan 17th, 2020 16:00
BID106.12 ASK106.17
Open110.14 Previous Close110.25
Pre-Market109.05 After-Market106.11
 -1.20 -1.09%  - -%
Target Price
153.06 
Analyst Rating
Moderate Buy 1.56
Potential %
44.25 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-56/-73 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-19/-43 
Growth Ranking
★+     42.59
Insiders Shares Cnt. % 3/6/12 mo.
-100/0/-23 
Income Ranking
 —    -
Market Cap (M)3 473 
Earnings Rating
Sell
Price Range Ratio 52W %
65.70 
Earnings Date
27th Feb 2020

Today's Price Range

105.05110.44

52W Range

56.76131.87

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Sell
Performance
1 Week
-7.99%
1 Month
-11.23%
3 Months
63.07%
6 Months
48.05%
1 Year
-6.88%
3 Years
-8.37%
5 Years
-29.56%
10 Years
-

TickerPriceChg.Chg.%
ICPT106.11-4.1400-3.76
AAPL317.812.57000.82
GOOG1 480.3928.69001.98
MSFT167.100.93000.56
XOM68.56-0.2600-0.38
WFC49.18-0.0700-0.14
JNJ149.170.97000.65
FB222.140.37000.17
GE11.81-0.0300-0.25
JPM138.200.95000.69
Earnings HistoryEstimateReportedSurprise %
Q03 2019-2.35-2.59-10.21
Q02 2019-2.51-2.289.16
Q01 2019-2.57-3.03-17.90
Q04 2018-2.42-2.97-22.73
Q03 2018-2.65-2.1817.74
Q02 2018-2.83-2.588.83
Q01 2018-3.41-3.225.57
Q04 2017-3.57-4.43-24.09
Earnings Per EndEstimateRevision %Trend
12/2019 QR-2.51-6.36Negative
12/2019 FY-10.30-4.57Negative
3/2020 QR-2.65-14.72Negative
12/2020 FY-10.30-7.52Negative
Next Report Date27th Feb 2020
Estimated EPS Next Report-2.51
Estimates Count10
EPS Growth Next 5 Years %-
Volume Overview
Volume1 292 425
Shares Outstanding (K)32 733
Trades Count7 359
Dollar Volume53 090 292
Avg. Volume630 296
Avg. Weekly Volume725 150
Avg. Monthly Volume576 948
Avg. Quarterly Volume654 563
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
13 (72.22 %)
14 (77.78 %)
13 (76.47 %)
Moderate Buy
2 (11.11 %)
2 (11.11 %)
2 (11.76 %)
Hold
2 (11.11 %)
1 (5.56 %)
1 (5.88 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (5.56 %)
1 (5.56 %)
1 (5.88 %)
RatingModerate Buy
1.56
Strong Buy
1.44
Strong Buy
1.47

Intercept Pharmaceuticals Inc.

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of China, where it has licensed out the product to Sumitomo Dainippon Pharma.

CEO: Mark Pruzanski

Teplephone: +1 646 747-1000

Address: 10 Hudson Yards, New York 10011, NY, USA

Number of employees: 483

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

22%78%

Bearish Bullish

70%30%

News

Stocktwits